U.S. stock-index futures added to gains Monday morning, with the market for risk assets gathering additional momentum from a report of success in a vaccine for the COVID=19 pandemic. Futures for the Dow Jones Industrial Average were up 614 points, or 2.6%, at 24,134, those for the S&P 500 index were up 2.5% at 2,916, while Nasdaq-100 futures advanced 2% at 9,276. The rally for the benchmark futures accelerated after a report on a phase one human trial (Moderna Inc. (MRNA) showed the production of antibodies to the virus in all of its 45 participants involved in the study.CNBC reported that participants ( ) in the trial received two doses of the potential vaccine via intramuscular injection in the upper arm approximately 28 days apart. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 ug," Tal Zaks, Moderna's chief medical officer, said in s statement. Bloomberg reported ( ) that the study is being conducted with the U.S. government, noting that Moderna will expand the trial.) for a coronavirus vaccine produced by
-Mark DeCambre; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
May 18, 2020 09:33 ET (13:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.